Medprin: The company's stock will resume trading on June 6 and continue to advance the issuance of shares and cash payment for asset purchases, as well as fundraising for supporting funds and related party transactions

Medprin announced that its stock will resume trading on June 6, 2025. The company held the tenth meeting of its third board of directors on June 5, where it reviewed and approved the proposal for issuing shares and paying cash to purchase assets and raise supporting funds, as well as related party transactions. The audit and evaluation work for the assets involved in this transaction has not yet been completed. The company will convene the board of directors again to review related matters after the relevant work is completed and submit it to the shareholders' meeting for approval. This transaction still requires approval from the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission before it can be officially implemented, which carries uncertainty. The company will continue to promote this transaction and strictly fulfill its information disclosure obligations